Pharmacology Flashcards
Where are cell bodies of the parasyympathetic preganglionic fibres located
Brainstem
Where are cell bodies of parasympathetic postganglionic fibres located
Bronchi and bronchiole walls
Stimulation of postganglionic cholinergenic fibres causes
Bronchial smooth muscle contraction (mediated by M3 ACH on ASM)
Increased mucus secretion (mediated by M3 ACH on goblet gland cells)
Stimulation of postganglionic noncholingergenic fibres causes
Bronchial smooth muscle relaxation (mediated by NO and VIP)
In the sympathetic division there is no innervation of
bronchial smooth muscle
Parasympathetic postganglionic fibres supply
Submucosal glands and smooth muscle of blood vessels
Stimulation of parasympathetic postganglionic fibres causes
Bronchial smooth muscle relaxation via B2- adrenoreceptors on ASM
Decreased mucus secretion mediated by B2-adrenoreceptors on goblet cells
Increased mucociliary clearance mediated by B2-adrenoreceptors on epithelial cells
Vascular smooth muscle contraction mediated by A1-adrenoreceptors on vascular smooth muscle cells
Contraction of smooth muscle caused by
Myosin light chain kinase phosphorylated
Relaxation of smooth muscle caused by
Dephosphorylation of Myosin phosphate
What causes the rate of phosphorylation to exceed rate of dephosphorylation
Presence of Ca2+
Relaxation requires Ca2+ to return to normal level
How does Ca2+ return to normal level
Active transport
Asthma
Recurrent, reversible obstruction of airways
Causes of asthma
Allergens
Exercise
Resp infection
Smoke, dust, environmental pollutants
Asthma patients present with
Tight chest
Wheeze
Cough
Difficulty breathing
Chronic asthma
Pathological changes that result from long standing inflammation:
- Increase mass of smooth muscle
- Accumulation of interstitial fluid
- Increased secretion of mucous
- Epithelial damage (exposing sensory nerve endings)
- Sub-epithelial fibrosis
Asthma caused FEV1 to
decrease
mild asthma displays
hypersensitivity
severe asthma displays
hypersensitivity
hyper-reactivity
FEV1
Forced expiratory volume in 1 second
In atopic individuals, stages of asthma immunity
- allergen
- phagocytosis
- Strong Th2 response, IgE
Development of allergic asthma
- Allergen in airway epithelium
- CD4+ express Th0 cells
- Th0 cells becomes Th2
- Th2 activates B cells
- B cells become IgE
- Th2 also release IL4 and IL13 causing mast cells to express IgE
- Stimulates Ca2+ entry, leukotriene release, contraction of smooth muscle
Stages in late phase of asthma
- Epithelial damage
- Airway hyper-responsiveness
- Bronchospasm, wheezing, cough, mucous over secretion
- Airway inflammation
2 categories of drugs used in treatment of asthma
Relievers (bronchodilators)
Controllers (Anti-inflammatory)
Relievers
SABA’s
LABA’s
CysLT1 receptors agonist
Controllers
Glucocorticoids
Cromoglicate
Humanised IgE monoclonal antibodies
B2 - adrenoreceptors agoinsts
antagonist of all spasmogens
Bronchodilators
SABA’s
Short Acting B2-adrenoreceptor Agonist
Salbutamol
Increase mucous clearance and decrease mediator release from mast cells and monocytes
LABA’s
Long Acting B2-adrenoreceptor Agonist
Salmeterol
Formaterol
Should not be used as monotherapy, should be used with gluticosteroids
used in nocturnal asthma
LABA
CysLT1
Cysteinyl Leukotriene Receptor Antagonists
Act competitively at CysLT1 receptor stopping smooth muscle contraction
Montelukast
Methylxanthines
Inhibits PDE3
Combine bronchodilator and anti-inflammatory actions
Second line drugs used with B2-adrenoreceptor agonists and glucocorticoids
Corticosteroids
Glucocorticoids Anti-inflammatory Reduces immunological response Prevent inflammation Resolve established inflammation
Cromones
Mast cell stabilisers
Weak anti-inflammatory response
Sodium cromoglicate
Reduce phases of asthma attack
More effective in young children
Monoclonal antibodies against IgE
Binds to IgE to prevent it binding to cells
Asthma Treatment
- SABA (salbutamol)
- Inhaled corticosteroid (beclomethasone)
- LABA + ICS (salmeterol)
- Increase glucocorticoid dose, add 4th drug
- Oral glucocorticoid (prednisolone)
Synthetic glucocorticoid used to prevent inflammation in chronic asthma
Inhaled beclometasone
Synthetic glucocorticoid used in severe or rapidly deteriorating asthma
Oral prednisolone
Weak anti-inflammatory used in allergic asthma
Inhaled Sodium Cromoglycate